Baxalta
Mar 28, 2017
Tesaro puts AstraZeneca; XELJANZ® receives; Innovus nabs; Alexion brings
Tesaro puts AstraZeneca on notice with early FDA nod for Lynparza rival niraparib Tesaro’s closely watched ovarian cancer drug niraparib—now dubbed Zejula—won an FDA nod on 27th March, months before its scheduled decision date. Apart from getting approval, Zejula also got a broader label than its head-to-head rival,...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
